KALA BIO reports FY23 net loss $42.2M; Phase 2b PCED trial data expected YE 2024

KALA BIO, Inc.

Q4 2023 net loss $8.6M ($3.18/sh) vs $12.8M ($7.97/sh) in Q4 2022.
FY 2023 net loss $42.2M ($17.35/sh) vs $44.8M ($29.48/sh) in FY 2022.
Cash $50.9M at Dec 31, 2023; with $8.6M Mar 2024 placement, runway into Q3 2025.
R&D expenses Q4 $4.7M (up from $3.3M) driven by KPI-012 development costs.
KPI-012 Phase 2b CHASE trial for PCED enrolling; topline data targeted by year-end 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

KALA BIO, Inc. reported financial results for the quarter and year ended December 31, 2023.

Period: the quarter and year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 29, 2024, KALA BIO, Inc. announced its financial results for the quarter and year ended December 31, 2023 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

KALA BIO, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-004325

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.